A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

Active:	Yes
Cancer Type:	Prostate Cancer Unknown Primary	NCT ID:	NCT06095089
Trial Phases:	Phase I	Protocol IDs:	CR109330 (primary) NCI-2023-09674 2023 2023-504063-17-00 87189401PCR1001
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Janssen Research & Development, LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06095089

Summary

The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen
for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of
Part 2C of this study is to determine how safe the RP2R(s) of the combination of
JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study
evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with
standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study
further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343
with JNJ-101556143 in participants with advanced prostate cancer.

Treatment Sites in Georgia

Emory University Hospital - Midtown
550 Peachtree Street NE
Atlanta, GA 30308
404-686-4411
www.emoryhealthcare.org

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.